ZBH Quote, Financials, Valuation and Earnings

Paragon 28 has a net margin of 11.84% compared to Zimmer Biomet Holdings's net margin of -15.5%. Zimmer Biomet Holdings's return on equity of 7.21% beat Paragon 28's return on equity of -36.38%.

Zimmer Biomet Holdings has a consensus price target of $122.27, signalling upside risk potential of 8.53%. On the other hand Paragon 28 has an analysts' consensus of $14.50 which suggests that it could grow by 10.94%. Given that Paragon 28 has higher upside potential than Zimmer Biomet Holdings, analysts believe Paragon 28 is more attractive than Zimmer Biomet Holdings.

Zimmer Biomet Holdings has a beta of 0.843, which suggesting that the stock is 15.664% less volatile than S&P 500. In comparison Paragon 28 has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Zimmer Biomet Holdings has a quarterly dividend of $0.24 per share corresponding to a yield of 0.85%. Paragon 28 offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zimmer Biomet Holdings pays 21.69% of its earnings as a dividend. Paragon 28 pays out -- of its earnings as a dividend. Zimmer Biomet Holdings's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Zimmer Biomet Holdings quarterly revenues are $2B, which are larger than Paragon 28 quarterly revenues of $71.7M. Zimmer Biomet Holdings's net income of $239.5M is higher than Paragon 28's net income of -$11.1M. Notably, Zimmer Biomet Holdings's price-to-earnings ratio is 25.32x while Paragon 28's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zimmer Biomet Holdings is 2.99x versus 4.25x for Paragon 28. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of 11.84% compared to Zimmer Biomet Holdings's net margin of 15.24%. Zimmer Biomet Holdings's return on equity of 7.21% beat Johnson & Johnson's return on equity of 19.98%.

Zimmer Biomet Holdings has a consensus price target of $122.27, signalling upside risk potential of 8.53%. On the other hand Johnson & Johnson has an analysts' consensus of $169.07 which suggests that it could grow by 5.79%. Given that Zimmer Biomet Holdings has higher upside potential than Johnson & Johnson, analysts believe Zimmer Biomet Holdings is more attractive than Johnson & Johnson.

Zimmer Biomet Holdings has a beta of 0.843, which suggesting that the stock is 15.664% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.490, suggesting its less volatile than the S&P 500 by 50.995%.

Zimmer Biomet Holdings has a quarterly dividend of $0.24 per share corresponding to a yield of 0.85%. Johnson & Johnson offers a yield of 3.1% to investors and pays a quarterly dividend of $1.24 per share. Zimmer Biomet Holdings pays 21.69% of its earnings as a dividend. Johnson & Johnson pays out 84.05% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Zimmer Biomet Holdings quarterly revenues are $2B, which are smaller than Johnson & Johnson quarterly revenues of $22.5B. Zimmer Biomet Holdings's net income of $239.5M is lower than Johnson & Johnson's net income of $3.4B. Notably, Zimmer Biomet Holdings's price-to-earnings ratio is 25.32x while Johnson & Johnson's PE ratio is 27.60x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zimmer Biomet Holdings is 2.99x versus 4.37x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of 11.84% compared to Zimmer Biomet Holdings's net margin of 32.59%. Zimmer Biomet Holdings's return on equity of 7.21% beat Eli Lilly and's return on equity of 80.24%.

Zimmer Biomet Holdings has a consensus price target of $122.27, signalling upside risk potential of 8.53%. On the other hand Eli Lilly and has an analysts' consensus of $1,010.47 which suggests that it could grow by 28.06%. Given that Eli Lilly and has higher upside potential than Zimmer Biomet Holdings, analysts believe Eli Lilly and is more attractive than Zimmer Biomet Holdings.

Zimmer Biomet Holdings has a beta of 0.843, which suggesting that the stock is 15.664% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.509, suggesting its less volatile than the S&P 500 by 49.093%.

Zimmer Biomet Holdings has a quarterly dividend of $0.24 per share corresponding to a yield of 0.85%. Eli Lilly and offers a yield of 0.68% to investors and pays a quarterly dividend of $1.50 per share. Zimmer Biomet Holdings pays 21.69% of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Zimmer Biomet Holdings quarterly revenues are $2B, which are smaller than Eli Lilly and quarterly revenues of $13.5B. Zimmer Biomet Holdings's net income of $239.5M is lower than Eli Lilly and's net income of $4.4B. Notably, Zimmer Biomet Holdings's price-to-earnings ratio is 25.32x while Eli Lilly and's PE ratio is 67.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zimmer Biomet Holdings is 2.99x versus 15.84x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals has a net margin of 11.84% compared to Zimmer Biomet Holdings's net margin of 31.35%. Zimmer Biomet Holdings's return on equity of 7.21% beat Vertex Pharmaceuticals's return on equity of -3.23%.

Zimmer Biomet Holdings has a consensus price target of $122.27, signalling upside risk potential of 8.53%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $497.84 which suggests that it could grow by 2.86%. Given that Zimmer Biomet Holdings has higher upside potential than Vertex Pharmaceuticals, analysts believe Zimmer Biomet Holdings is more attractive than Vertex Pharmaceuticals.

Zimmer Biomet Holdings has a beta of 0.843, which suggesting that the stock is 15.664% less volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.504, suggesting its less volatile than the S&P 500 by 49.617%.

Zimmer Biomet Holdings has a quarterly dividend of $0.24 per share corresponding to a yield of 0.85%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zimmer Biomet Holdings pays 21.69% of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend. Zimmer Biomet Holdings's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Zimmer Biomet Holdings quarterly revenues are $2B, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.9B. Zimmer Biomet Holdings's net income of $239.5M is lower than Vertex Pharmaceuticals's net income of $913M. Notably, Zimmer Biomet Holdings's price-to-earnings ratio is 25.32x while Vertex Pharmaceuticals's PE ratio is 26.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zimmer Biomet Holdings is 2.99x versus 11.39x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.